Digihaler in Chronic Obstructive Pulmonary Disease (COPD)
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a multi-center 3-month study to determine the variation in ProAir Digihaler metrics
[peak inspiratory flow (PIF), inhalation volume, number of inhalation events] amongst COPD
patients in the ambulatory setting.
Phase:
Early Phase 1
Details
Lead Sponsor:
University of North Carolina, Chapel Hill
Collaborators:
Teva Branded Pharmaceutical Products R&D, Inc. Wake Forest University Health Sciences